Matthew Taylor
Stock Analyst at Jefferies
(3.42)
# 867
Out of 4,829 analysts
174
Total ratings
60%
Success rate
10.8%
Average return
Main Sectors:
Stocks Rated by Matthew Taylor
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ABT Abbott Laboratories | Maintains: Hold | $135 → $137 | $133.24 | +2.82% | 13 | Apr 17, 2025 | |
| INMD InMode | Maintains: Hold | $16 → $15 | $14.45 | +3.81% | 7 | Apr 14, 2025 | |
| GEHC GE HealthCare Technologies | Upgrades: Buy | $95 → $103 | $69.87 | +47.42% | 2 | Jan 8, 2025 | |
| EW Edwards Lifesciences | Downgrades: Hold | $85 → $70 | $73.68 | -4.99% | 19 | Sep 18, 2024 | |
| PODD Insulet | Maintains: Neutral | $211 → $223 | $310.67 | -28.22% | 14 | Aug 9, 2024 | |
| MDT Medtronic | Maintains: Sell | $75 → $76 | $83.48 | -8.96% | 17 | May 24, 2024 | |
| ALUR Allurion Technologies | Initiates: Buy | $125 | $2.38 | +5,152.10% | 1 | Feb 9, 2024 | |
| MASI Masimo | Downgrades: Hold | $107 → $121 | $156.57 | -22.72% | 9 | Jan 30, 2024 | |
| OBIO Orchestra BioMed Holdings | Initiates: Buy | $14 | $2.65 | +428.30% | 1 | Jan 19, 2024 | |
| TNDM Tandem Diabetes Care | Maintains: Buy | $47 → $45 | $22.98 | +95.82% | 2 | Oct 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Underperform | $0.5 | $0.63 | -20.00% | 1 | Jul 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $58 → $53 | $12.25 | +332.65% | 2 | Jul 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $22 → $24 | $6.88 | +248.84% | 2 | May 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $320 → $345 | $380.92 | -9.43% | 14 | May 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Hold | $115 → $130 | $95.21 | +36.54% | 8 | Mar 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $230 | $297.32 | -22.64% | 1 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $18.49 | +8.17% | 1 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $85 | $57.08 | +48.91% | 1 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $75 | $55.82 | +34.36% | 7 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $245 | $245.04 | -0.02% | 7 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $62 | $30.90 | +100.65% | 8 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $210 | $125.11 | +67.85% | 1 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $12.21 | -1.72% | 1 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $125 | $84.67 | +47.63% | 12 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $50 | $102.86 | -51.39% | 1 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $210 | $536.51 | -60.86% | 12 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $96 | $44.06 | +117.88% | 3 | Feb 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $7 | $2.23 | +213.90% | 1 | Dec 17, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $266 | $167.22 | +59.07% | 4 | May 13, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $17 → $16 | $9.11 | +75.63% | 2 | Jul 19, 2017 |
Abbott Laboratories
Apr 17, 2025
Maintains: Hold
Price Target: $135 → $137
Current: $133.24
Upside: +2.82%
InMode
Apr 14, 2025
Maintains: Hold
Price Target: $16 → $15
Current: $14.45
Upside: +3.81%
GE HealthCare Technologies
Jan 8, 2025
Upgrades: Buy
Price Target: $95 → $103
Current: $69.87
Upside: +47.42%
Edwards Lifesciences
Sep 18, 2024
Downgrades: Hold
Price Target: $85 → $70
Current: $73.68
Upside: -4.99%
Insulet
Aug 9, 2024
Maintains: Neutral
Price Target: $211 → $223
Current: $310.67
Upside: -28.22%
Medtronic
May 24, 2024
Maintains: Sell
Price Target: $75 → $76
Current: $83.48
Upside: -8.96%
Allurion Technologies
Feb 9, 2024
Initiates: Buy
Price Target: $125
Current: $2.38
Upside: +5,152.10%
Masimo
Jan 30, 2024
Downgrades: Hold
Price Target: $107 → $121
Current: $156.57
Upside: -22.72%
Orchestra BioMed Holdings
Jan 19, 2024
Initiates: Buy
Price Target: $14
Current: $2.65
Upside: +428.30%
Tandem Diabetes Care
Oct 2, 2023
Maintains: Buy
Price Target: $47 → $45
Current: $22.98
Upside: +95.82%
Jul 19, 2023
Initiates: Underperform
Price Target: $0.5
Current: $0.63
Upside: -20.00%
Jul 12, 2023
Upgrades: Buy
Price Target: $58 → $53
Current: $12.25
Upside: +332.65%
May 24, 2023
Maintains: Hold
Price Target: $22 → $24
Current: $6.88
Upside: +248.84%
May 2, 2023
Maintains: Buy
Price Target: $320 → $345
Current: $380.92
Upside: -9.43%
Mar 31, 2023
Upgrades: Hold
Price Target: $115 → $130
Current: $95.21
Upside: +36.54%
Oct 12, 2022
Initiates: Buy
Price Target: $230
Current: $297.32
Upside: -22.64%
Oct 12, 2022
Initiates: Buy
Price Target: $20
Current: $18.49
Upside: +8.17%
Oct 12, 2022
Initiates: Hold
Price Target: $85
Current: $57.08
Upside: +48.91%
Oct 12, 2022
Initiates: Buy
Price Target: $75
Current: $55.82
Upside: +34.36%
Oct 12, 2022
Initiates: Hold
Price Target: $245
Current: $245.04
Upside: -0.02%
Oct 12, 2022
Initiates: Hold
Price Target: $62
Current: $30.90
Upside: +100.65%
Oct 12, 2022
Initiates: Hold
Price Target: $210
Current: $125.11
Upside: +67.85%
Oct 12, 2022
Initiates: Buy
Price Target: $12
Current: $12.21
Upside: -1.72%
Oct 12, 2022
Initiates: Buy
Price Target: $125
Current: $84.67
Upside: +47.63%
Oct 12, 2022
Initiates: Buy
Price Target: $50
Current: $102.86
Upside: -51.39%
Oct 12, 2022
Initiates: Hold
Price Target: $210
Current: $536.51
Upside: -60.86%
Feb 24, 2022
Upgrades: Buy
Price Target: $96
Current: $44.06
Upside: +117.88%
Dec 17, 2021
Initiates: Neutral
Price Target: $7
Current: $2.23
Upside: +213.90%
May 13, 2019
Upgrades: Overweight
Price Target: $266
Current: $167.22
Upside: +59.07%
Jul 19, 2017
Maintains: Equal-Weight
Price Target: $17 → $16
Current: $9.11
Upside: +75.63%